Collplant Holdings (CLGN)
NASDAQ:CLGN
Want to see CLGN full AI Analyst Report?
CLGN Stock Chart & Stats
$1.51
-$0.10(-2.34%)
At close: 4:00 PM EST
$1.51
-$0.10(-2.34%)
Day’s Range― - ―
52-Week Range$0.27 - $4.98
Previous CloseN/A
Volume800.00
Average Volume (3M)29.18K
Market Cap
$6.15M
Enterprise Value$2.11M
Total Cash (Recent Filing)$5.95M
Total Debt (Recent Filing)$2.85M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding14,415,128
10 Day Avg. Volume15,198
30 Day Avg. Volume29,183
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.81
Price to Sales (P/S)7.21
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda-0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
PartnershipsCollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.
Product DevelopmentEncouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.
Bears Say
Financial PerformanceThe company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.
Collplant Holdings News
CLGN FAQ
What was Collplant Holdings’s price range in the past 12 months?
Collplant Holdings lowest stock price was $0.27 and its highest was $4.98 in the past 12 months.
What is Collplant Holdings’s market cap?
Collplant Holdings’s market cap is $6.15M.
When is Collplant Holdings’s upcoming earnings report date?
Collplant Holdings’s upcoming earnings report date is Aug 20, 2026 which is in 85 days.
How were Collplant Holdings’s earnings last quarter?
Currently, no data Available
Is Collplant Holdings overvalued?
According to Wall Street analysts Collplant Holdings’s price is currently Overvalued.
Does Collplant Holdings pay dividends?
Collplant Holdings does not currently pay dividends.
What is Collplant Holdings’s EPS estimate?
Collplant Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Collplant Holdings have?
Collplant Holdings has 14,415,128 shares outstanding.
What happened to Collplant Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Collplant Holdings?
Currently, no hedge funds are holding shares in CLGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Collplant Holdings
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Technical Analysis
Daré Bioscience
―
Passage Bio
―
PolyPid
―
SAB Biotherapeutics
―
Neurosense Therapeutics Ltd.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
10.85% Other Institutional Investors
89.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---